A Phase 3 interventional study of Immune Globulin Subcutaneous (Human) (SCIG) in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 10 sites in Japan. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-12.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2010, is one of 9 in phase 3, and was the 9th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: Up to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 25 across the 13 interventional studies, 27 across the 1 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics of a subcutaneous immune globulin (SCIG; IgPro20) in subjects with primary immunodeficiency (PID). In addition, the study will assess the health-related quality of life and pharmacoeconomic aspects related to treatment with IgPro20.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Immune Globulin Subcutaneous (Human) (SCIG)
IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
Also known as: Hizentra
IgG Trough Level
Geometric means of trough levels measured before 3 intravenous immunoglobulin (IVIG) infusions was compared with those of trough levels measured at steady-state for 3 subcutaneous immunoglobulin (SCIG) infusions (weeks 16, 20 and 24). The ratio of these geometric means was the primary outcome measure.
Time frame: During IVIG period (IV 1, IV 2, IV 3) and during SCIG period at weeks 16, 20, and 24
Number of Infection Episodes (Serious and Non-serious) by Study Period
Number of infection episodes (serious and non-serious) presented by study period: * IVIG treatment: Study subjects were treated with their IVIG therapy with 3- or 4-weekly schedules for 3 dosing cycles (9 to 12 weeks; before being switched to SCIG treatment with IgPro20). * SCIG treatment (wash-in/wash-out; weeks 1 to 12): IgPro20 was administered subcutaneously with the first subcutaneous (SC) IgPro20 infusion starting 1 week after the last IVIG dose. Subjects were treated with weekly SC IgPro20 infusions for a 12-week wash-in/wash-out period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy. * SCIG treatment (efficacy; weeks 13 to 24): After the SCIG wash-in/wash-out treatment, subjects were treated with weekly SC IgPro20 infusions for a 12-week efficacy period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy.
Time frame: Up to 36 weeks
Rate of Infection Episodes (Serious and Non-serious) by Study Period, PPS Population
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks) * SCIG IgPro20 treatment (efficacy) (12 weeks)
Time frame: Up to 36 weeks
Rate of Infection Episodes (Serious and Non-serious) by Study Period, FAS Population
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks) * SCIG IgPro20 treatment (efficacy) (12 weeks)
Time frame: Up to 36 weeks
Number of Days Out of Work/School/Kindergarten/Day Care or Unable to Perform Normal Daily Activities Due to Infections by Study Period
Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
Time frame: Up to 36 weeks
Number of Days of Hospitalization Due to Infections by Study Period
Median number of days of hospitalization due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
Time frame: Up to 36 weeks
Duration of Use of Antibiotics for Infection Prophylaxis and Treatment
Median number of days of use of antibiotics for infection prophylaxis and/or treatment, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
Time frame: Up to 36 weeks
Rate of All Adverse Events by Relatedness and Seriousness
The rate of adverse events (AEs) was the number of treatment-emergent AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
Time frame: For the duration of the study, up to 36 weeks
Rate of Mild, Moderate, or Severe Local Reactions
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of: infusion site discomfort, infusion site erythema, infusion site haemorrhage, infusion site induration, infusion site inflammation, infusion site pain, infusion site pruritus, infusion site swelling, injection site erythema, injection site extravasation, injection site induration, injection site irritation, injection site pain, injection site pruritus, injection site swelling, and puncture site reaction. Mild AE: Symptoms are easily tolerated and there is no interference with daily activities; Moderate AE: Discomfort enough to cause some interference with daily activities; Severe AE: Incapacitating with inability to work or do usual activity.
Time frame: For the duration of the study, up to 36 weeks
Annualized Rate of Serious Bacterial Infections (SBIs), PPS Population
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks) * SCIG IgPro20 treatment (efficacy; 12 weeks)
Time frame: Up to 36 weeks
Annualized Rate of Serious Bacterial Infections (SBIs), FAS Population
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks) * SCIG IgPro20 treatment (efficacy; 12 weeks)
Time frame: Up to 36 weeks
This multicenter study enrolled subjects at nine of the participating study centers in Japan.
| Milestone | IgPro20 |
|---|---|
| Started | 25 |
| Completed | 25 |
| Not completed | 0 |
| Milestone | IgPro20 |
|---|---|
| Started | 25 |
| Completed | 24 |
| Not completed | 1 |
| Withdrew: Transfer of residence | 1 |
| Milestone | IgPro20 |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
Geometric means of trough levels measured before 3 intravenous immunoglobulin (IVIG) infusions was compared with those of trough levels measured at steady-state for 3 subcutaneous immunoglobulin (SCIG) infusions (weeks 16, 20 and 24). The ratio of these geometric means was the primary outcome measure.
| Ratio of Geometric Means | IgPro20 - Per Protocol Set (PPS) | IgPro20 - Full Analysis Set (FAS) |
|---|---|---|
| IgG Trough Level | 1.09 (1.06 to 1.13) | 1.11 (1.08 to 1.15) |
Number of infection episodes (serious and non-serious) presented by study period: * IVIG treatment: Study subjects were treated with their IVIG therapy with 3- or 4-weekly schedules for 3 dosing cycles (9 to 12 weeks; before being switched to SCIG treatment with IgPro20). * SCIG treatment (wash-in/wash-out; weeks 1 to 12): IgPro20 was administered subcutaneously with the first subcutaneous (SC) IgPro20 infusion starting 1 week after the last IVIG dose. Subjects were treated with weekly SC IgPro20 infusions for a 12-week wash-in/wash-out period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy. * SCIG treatment (efficacy; weeks 13 to 24): After the SCIG wash-in/wash-out treatment, subjects were treated with weekly SC IgPro20 infusions for a 12-week efficacy period. The IgPro20 dose was to be equal to the weekly equivalent dose of the previous IVIG therapy.
| Number of infection episodes | IgPro20 - Per Protocol Set (PPS) | IgPro20 - Full Analysis Set (FAS) |
|---|---|---|
| IVIG Treatment | 19 | 22 |
| SCIG IgPro20 Treatment (Wash-in/Wash-out) | 28 | 32 |
| SCIG IgPro20 Treatment (Efficacy) | 15 | 18 |
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks) * SCIG IgPro20 treatment (efficacy) (12 weeks)
| Infections per subject year | IVIG Treatment | SCIG Treatment (Wash-in/Wash-out) | SCIG Treatment (Efficacy) |
|---|---|---|---|
| Rate of Infection Episodes (Serious and Non-serious) by Study Period, PPS Population | 5.74 | 5.79 | 2.98 |
The annualized rate of infection episodes (serious and non-serious) was based on the total number of infection episodes and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out period) (12 weeks) * SCIG IgPro20 treatment (efficacy) (12 weeks)
| Infections per subject year | IVIG Treatment | SCIG Treatment (Wash-in/Wash-out) | SCIG Treatment (Efficacy) |
|---|---|---|---|
| Rate of Infection Episodes (Serious and Non-serious) by Study Period, FAS Population | 5.75 | 5.79 | 3.14 |
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks) * SCIG IgPro20 treatment (efficacy; 12 weeks)
| SBIs per subject year | IVIG Treatment | SCIG IgPro20 Treatment (Wash-in/Wash-out) | SCIG IgPro20 Treatment (Efficacy) |
|---|---|---|---|
| Annualized Rate of Serious Bacterial Infections (SBIs), PPS Population | 0.00 | 0.00 | 0.00 |
Median number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
| Days | IgPro20 - Per Protocol Set (PPS) | IgPro20 - Full Analysis Set (FAS) |
|---|---|---|
| IVIG Treatment | 0 (0 to 8) | 0 (0 to 8) |
| SCIG IgPro20 Treatment (Wash-in/Wash-out) | 0 (0 to 9) | 0 (0 to 9) |
| SCIG IgPro20 Treatment (Efficacy) | 0 (0 to 8) | 0 (0 to 8) |
The annualized rate was based on the total number of SBIs and the total number of subject study days for all subjects in the specified study periods (listed below) and analysis population and adjusted to 365 days. Study periods: * IVIG treatment (up to 12 weeks) * SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks) * SCIG IgPro20 treatment (efficacy; 12 weeks)
| SBIs per subject year | IVIG Treatment | SCIG IgPro20 Treatment (Wash-in/Wash-out) | SCIG IgPro20 Treatment (Efficacy) |
|---|---|---|---|
| Annualized Rate of Serious Bacterial Infections (SBIs), FAS Population | 0.00 | 0.00 | 0.00 |
Median number of days of hospitalization due to infections, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
| Days | IgPro20 - Per Protocol Set (PPS) | IgPro20 - Full Analysis Set (FAS) |
|---|---|---|
| IVIG Treatment | 0 (0 to 1) | 0 (0 to 1) |
| SCIG IgPro20 Treatment (Wash-in/Wash-out) | 0 (0 to 0) | 0 (0 to 0) |
| SCIG IgPro20 Treatment (Efficacy) | 0 (0 to 3) | 0 (0 to 3) |
Median number of days of use of antibiotics for infection prophylaxis and/or treatment, presented by study period: IVIG treatment (up to 12 weeks), SCIG IgPro20 treatment (wash-in/wash-out; 12 weeks), and SCIG IgPro20 treatment (efficacy; 12 weeks).
| Days | IgPro20 - Per Protocol Set (PPS) | IgPro20 - Full Analysis Set (FAS) |
|---|---|---|
| IVIG Treatment | 48.5 (2 to 64) | 48.0 (2 to 64) |
| SCIG IgPro20 Treatment (Wash-in/Wash-out) | 49.0 (3 to 86) | 35.5 (2 to 86) |
| SCIG IgPro20 Treatment (Efficacy) | 71.0 (6 to 85) | 71.0 (6 to 85) |
The rate of adverse events (AEs) was the number of treatment-emergent AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.
| AEs per infusion | IVIG Treatment | SCIG Treatment |
|---|---|---|
| All AEs | 0.653 | 0.457 |
| At Least Possibly Related AEs | 0.027 | 0.296 |
| Serious AEs | 0 | 0.002 |
| At Least Possibly Related and Serious AEs | 0 | 0 |
In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of: infusion site discomfort, infusion site erythema, infusion site haemorrhage, infusion site induration, infusion site inflammation, infusion site pain, infusion site pruritus, infusion site swelling, injection site erythema, injection site extravasation, injection site induration, injection site irritation, injection site pain, injection site pruritus, injection site swelling, and puncture site reaction. Mild AE: Symptoms are easily tolerated and there is no interference with daily activities; Moderate AE: Discomfort enough to cause some interference with daily activities; Severe AE: Incapacitating with inability to work or do usual activity.
| AEs per infusion | IVIG Treatment | SCIG Treatment |
|---|---|---|
| Mild Local Reactions | 0 | 0.274 |
| Moderate Local Reactions | 0 | 0 |
| Severe Local Reactions | 0 | 0 |
Collected over For the duration of the study, up to 36 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IVIG Treatment | — | 1/25 (4%) | 20/25 (80%) |
| SCIG Treatment | — | 1/25 (4%) | 24/25 (96%) |
| Event | IVIG Treatment | SCIG Treatment |
|---|---|---|
| Bacterial infectionInfections and infestations | 0/25 | 1/25 |
| GastroenteritisInfections and infestations | 1/25 | 0/25 |
| Event | IVIG Treatment | SCIG Treatment |
|---|---|---|
| Local reactionsGeneral disorders | 0/25 | 20/25 |
| NasopharyngitisInfections and infestations | 5/25 | 11/25 |
| Upper respiratory tract infectionInfections and infestations | 4/25 | 5/25 |
| InfluenzaInfections and infestations | 4/25 | 4/25 |
| Dental cariesGastrointestinal disorders | 1/25 | 3/25 |
| BronchitisInfections and infestations | 0/25 | 3/25 |
| GastroenteritisInfections and infestations | 1/25 | 3/25 |
| SinusitisInfections and infestations | 0/25 | 3/25 |
| Arthropod biteInjury, poisoning and procedural complications | 0/25 | 3/25 |
| HeadacheNervous system disorders | 3/25 | 1/25 |
| Age, Continuous(Years) | IgPro20 |
|---|---|
| Mean | 20.6 ± 13.23 |
| Age, Customized(Participants) | IgPro20 |
|---|---|
| < 2 years | 0 |
| ≥ 2 to < 12 years | 7 |
| ≥ 12 to ≤ 16 years | 4 |
| > 16 to < 65 years | 14 |
| ≥ 65 years | 0 |
| Sex: Female, Male(Participants) | IgPro20 |
|---|---|
| Female | 9 |
| Male | 16 |
| Primary Immunodeficiency Type(Participants) | IgPro20 |
|---|---|
| Common Variable Immunodeficiency (CVID) | 10 |
| X-Linked Agammaglobulinemia (XLA) | 13 |
| Autosomal Recessive Agammaglobulinemia (ARAG) | 1 |
| Hyper-Immunoglobulin M (IgM) Syndrome | 1 |
The record gives a start of Sep 2010, a primary completion of Aug 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Primary Immunodeficiency Diseases →